retatrutide ly3437943 parkinson's disease clinical trial for Obesity · Info for Participants · Phase Phase 1 2026 | Power Parkinson's research trial numbers remain

ranges from around $900 to $1,400 per month

Deepest pipeline: Eli Lilly leads in pipeline breadth and modality diversification approved assets across three distinct MoA classes (GLP-1R mono, GLP-1R/GIPR dual, oral SM, triple agonist in Phase 3)

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, compared to semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP)

GLP-1 receptor agonists significantly impair taste function

Real Life Situation : A company sees a significant increase in their pharmacy spends as more employees begin prescriptions for Ozempic, Wegovy, Mounjaro or similar medications, putting pressure on their budgets

Published data (STEP 4, JAMA 2022) show that most patients regain a portion of lost weight after discontinuation